Literature DB >> 26013205

The Correlation Between RhoA Expression and Clinicopathological Characteristics in Gastric Cancer Patients After Curative Surgery.

Kuo-Hung Huang1, Yuan-Tzu Lan, Ming-Huang Chen, Yee Chao, Su-Shun Lo, Anna Fen-Yau Li, Chew-Wun Wu, Shih-Hwa Chiou, Muh-Hwa Yang, Yi-Ming Shyr, Wen-Liang Fang.   

Abstract

BACKGROUND: The expression of RhoA, a member of the ras homologue family, is reported to be involved in tumorigenesis in some cancers; however, its prognostic value in gastric cancer is controversial.
METHODS: Between April 1988 and January 2005, a total of 206 gastric cancer patients receiving curative surgery were enrolled in this study. Immunohistochemical staining of the RhoA protein was performed, and the clinicopathological characteristics and initial recurrence patterns were compared between low RhoA expression (n = 55) and high RhoA expression (n = 151) gastric cancer patients.
RESULTS: For intestinal-type (n = 134) gastric cancer, there is no significant difference between the clinicopathological characteristics and RhoA expression. However, for diffuse-type (n = 82) gastric cancer, high RhoA expression was associated with more advanced pathological N category compared to low RhoA expression. A multivariate analysis revealed that age, pathological T and N categories, and RhoA expression were independent prognostic factors for overall survival after curative surgery. For all patients, the five-year overall survival rates and disease-free survival rates were higher in patients with low RhoA expression compared to those with high RhoA expression, which was observed in diffuse-type gastric cancer, not in intestinal-type gastric cancer. With regard to the initial recurrence pattern, patients with high RhoA expression had more distant metastasis compared to those with low RhoA expression, especially more liver metastasis.
CONCLUSIONS: RhoA expression is an independent prognostic factor for gastric cancer, especially for diffuse-type. We should be aware of liver metastasis during the follow-up of gastric cancer with high RhoA expression.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26013205     DOI: 10.1007/s00268-015-3095-4

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  33 in total

1.  Integrin-mediated adhesion regulates cell polarity and membrane protrusion through the Rho family of GTPases.

Authors:  E A Cox; S K Sastry; A Huttenlocher
Journal:  Mol Biol Cell       Date:  2001-02       Impact factor: 4.138

2.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

3.  Rho GTPases are over-expressed in human tumors.

Authors:  G Fritz; I Just; B Kaina
Journal:  Int J Cancer       Date:  1999-05-31       Impact factor: 7.396

4.  RhoA is associated with invasion and lymph node metastasis in upper urinary tract cancer.

Authors:  T Kamai; S Kawakami; F Koga; G Arai; K Takagi; K Arai; T Tsujii; K-I Yoshida
Journal:  BJU Int       Date:  2003-02       Impact factor: 5.588

5.  TrkBT1 induces liver metastasis of pancreatic cancer cells by sequestering Rho GDP dissociation inhibitor and promoting RhoA activation.

Authors:  Zhongkui Li; Zhe Chang; Lucia J Chiao; Ya'an Kang; Qianghua Xia; Cihui Zhu; Jason B Fleming; Douglas B Evans; Paul J Chiao
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

6.  p27Kip1 modulates cell migration through the regulation of RhoA activation.

Authors:  Arnaud Besson; Mark Gurian-West; Anja Schmidt; Alan Hall; James M Roberts
Journal:  Genes Dev       Date:  2004-04-12       Impact factor: 11.361

7.  ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility.

Authors:  Emmanuel Vial; Erik Sahai; Christopher J Marshall
Journal:  Cancer Cell       Date:  2003-07       Impact factor: 31.743

8.  The activity of RhoA is correlated with lymph node metastasis in human colorectal cancer.

Authors:  Yoji Takami; Morihiro Higashi; Shinpei Kumagai; Paul C Kuo; Hidetada Kawana; Keiji Koda; Masaru Miyazaki; Kenichi Harigaya
Journal:  Dig Dis Sci       Date:  2007-06-28       Impact factor: 3.199

9.  Loss of p57 expression and RhoA overexpression are associated with poor survival of patients with hepatocellular carcinoma.

Authors:  Tinghua Hu; Hui Guo; Wenjuan Wang; Shuo Yu; Lili Han; Lili Jiang; Jiequn Ma; Chengcheng Yang; Qianqian Guo; Kejun Nan
Journal:  Oncol Rep       Date:  2013-07-09       Impact factor: 3.906

10.  Abnormal expression of p120-catenin, E-cadherin, and small GTPases is significantly associated with malignant phenotype of human lung cancer.

Authors:  Yang Liu; Yan Wang; Yong Zhang; Yuan Miao; Yue Zhao; Peng-Xin Zhang; Gui-Yang Jiang; Jun-Yi Zhang; Yang Han; Xu-Yong Lin; Lian-He Yang; Qing-Chang Li; Chen Zhao; En-Hua Wang
Journal:  Lung Cancer       Date:  2009-01-21       Impact factor: 5.705

View more
  11 in total

1.  The role of RhoA in vulvar squamous cell carcinoma: a carcinogenesis, progression, and target therapy marker.

Authors:  Jing Wang; Qiong Wu; Li-Hua Zhang; Yun-Xia Zhao; Xin Wu
Journal:  Tumour Biol       Date:  2015-09-26

2.  Differential role of Wnt signaling and base excision repair pathways in gastric adenocarcinoma aggressiveness.

Authors:  Alireza Korourian; Raheleh Roudi; Ahmad Shariftabrizi; Elham Kalantari; Kambiz Sotoodeh; Zahra Madjd
Journal:  Clin Exp Med       Date:  2016-12-01       Impact factor: 3.984

3.  Gastrokine 1 inhibits gastric cancer cell migration and invasion by downregulating RhoA expression.

Authors:  Jung Hwan Yoon; Won Suk Choi; Olga Kim; Byung Joon Choi; Suk Woo Nam; Jung Young Lee; Won Sang Park
Journal:  Gastric Cancer       Date:  2016-06-01       Impact factor: 7.370

4.  MiR-31 Regulates Rho-Associated Kinase-Myosin Light Chain (ROCK-MLC) Pathway and Inhibits Gastric Cancer Invasion: Roles of RhoA.

Authors:  Zhuo Chen; Shengnan Liu; Yuan Xia; Kejian Wu
Journal:  Med Sci Monit       Date:  2016-12-01

5.  Expressions of Ras Homolog Gene Family, Member A (RhoA) and Cyclooxygenase-2 (COX-2) Proteins in Early Gastric Cancer and Their Role in the Development of Gastric Cancer.

Authors:  Li Song; Yali Guo; Baohong Xu
Journal:  Med Sci Monit       Date:  2017-06-18

6.  A high expression ratio of RhoA/RhoB is associated with the migratory and invasive properties of basal-like Breast Tumors.

Authors:  Maud Privat; Amélie Cavard; Yanis Zekri; Flora Ponelle-Chachuat; Ioana Molnar; Nicolas Sonnier; Yves-Jean Bignon
Journal:  Int J Med Sci       Date:  2020-10-01       Impact factor: 3.738

7.  Identification of "regulation of RhoA activity panel" as a prognostic and predictive biomarker for gastric cancer.

Authors:  Wenwen Huang; Songhui Zhao; Cheng Zhang; Zhongwu Li; Sai Ge; Baofeng Lian; Hui Feng; Kai Wang; Ruihua Xu; Jiafu Ji; Jing Gao; Weiwei Shi; Lin Shen
Journal:  Aging (Albany NY)       Date:  2020-12-03       Impact factor: 5.682

8.  RhoA, Claudin 18, and c-MET in Gastric Cancer: Clinicopathological Characteristics and Prognostic Significance in Curative Resected Patients.

Authors:  Marina Alessandra Pereira; Marcus Fernando Kodama Pertille Ramos; Andre Roncon Dias; Leonardo Cardili; Renan Ribeiro E Ribeiro; Tiago Biachi de Castria; Bruno Zilberstein; Sergio Carlos Nahas; Ulysses Ribeiro; Evandro Sobroza de Mello
Journal:  Med Sci (Basel)       Date:  2021-12-29

9.  Inhibition of Rho-Associated Kinase 1/2 Attenuates Tumor Growth in Murine Gastric Cancer.

Authors:  Isabel Hinsenkamp; Sandra Schulz; Mareike Roscher; Anne-Maria Suhr; Björn Meyer; Bogdan Munteanu; Jens Fuchser; Stefan O Schoenberg; Matthias P A Ebert; Björn Wängler; Carsten Hopf; Elke Burgermeister
Journal:  Neoplasia       Date:  2016-08       Impact factor: 5.715

10.  Impact of RhoA overexpression on clinical outcomes in cervical squamous cell carcinoma treated with concurrent chemoradiotherapy.

Authors:  Keiichi Tanaka; Yoshitaka Matsumoto; Hitoshi Ishikawa; Nobuyoshi Fukumitsu; Haruko Numajiri; Keiko Murofushi; Yoshiko Oshiro; Toshiyuki Okumura; Toyomi Satoh; Hideyuki Sakurai
Journal:  J Radiat Res       Date:  2020-03-23       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.